selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar]
selegiline hydrochloride
RxCUI: 859192
What the CMS Formulary Data Shows for selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar]
Per the CMS 2026 Part D formulary file, selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] (RxNorm concept RXCUI 859192, generic name selegiline hydrochloride) appears on 5 distinct formulary files spanning 138 Medicare Part D plan offerings - 2.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 5, with a cross-plan average of Tier 4.8.
Real-world access to selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 877 Part D beneficiaries filled selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] in 2023, with total plan-and-beneficiary spending of $12,397,890 and an average per-beneficiary annual cost of $14,136.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 138
- Coverage rate
- 2.7%
- Tier range
- Tier 4 – Tier 5
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 877
- Total spending
- $12,397,890
- Avg per beneficiary
- $14,136.70
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] covered by Medicare Part D?
Yes, selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] is covered by 138 Medicare Part D plans (2.7% of all Part D formularies).
What tier is selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] on Medicare Part D plans?
selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] averages Tier 4.8 across Part D plans, ranging from Tier 4 to Tier 5.
Does selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] require prior authorization?
0% of Part D formularies require prior authorization for selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar]?
In 2023, total Medicare Part D spending on selegiline hydrochloride 1.25 MG Disintegrating Oral Tablet [Zelapar] was $12,397,890, covering 877 beneficiaries. The average spend per beneficiary was $14,136.70.
Read our methodology - how this data is sourced, computed, and verified.